(To see other currencies, click on price)
MORE ABOUT THIS BOOK
Main description:
The field of toxicogenomics is moving rapidly, so it is impossible at the timeofthiswritingtocompileaclassicmethodstextbook.Instead,wechose to identify experts in all aspects of this field and challenged them to write reviews, opinion pieces, and case studies. This book covers the main areas important to the study and use of toxicogenomics. Chapter 1 speaks to the convergenceofclassicapproachesalongsidetoxicogenomics.Chapter2deals withtheusefulnessoftoxicogenomicstoidentifythemechanismoftoxicity. Chapter3callsattentiontotheissuesthataffectthequalityoftoxicogenomics experiments, as well as the implications of using microarrays as diagnostic devices. The need for appropriate statistical approaches to genomic data is discussed in Chapter 4, and Chapters 5 and 6 describe the use of genomic datatobuildtoxicogenomicmodelsandprovideinsightsfromtheapproaches oftwocompanies.Theimportanttopicofstoringthedatageneratedinsuch experiments and the correct annotation that must accompany such data is considered in Chapter 7. The discussion in Chapter 8 speaks to the use of toxicogenomicstoidentifyspeciessimilaritiesanddifferences.Chapters9and 10dealwiththeuseofgenomicstoidentifybiomarkerswithinthepreclinical andclinicalarenas.
Biomarkerswillonlybeusefulifthecommunityatlarge acceptsthemasmeaningful.Consortiaareimportanttodrivethisfunction,and Chapter11discussescurrenteffortsinthisarea.Lastbutnotleast,Chapter12 presentsaperspectiveontheregulatoryimplicationsoftoxicogenomicdataand someofthehurdlesthatcanbeseeninitsimplicationinGLPstudies.Although thisbooktendstofocusonpharmaceuticals,theissuesfacingtoxicologyare sharedbythechemicalmanufacturers,thetobaccoindustry,andtheirregulators. We want to thank our contributors for their generous time and energy in providingtheirinsights.Sadly,wemustnotetheunexpectedpassingofone ofourauthors,Dr.JosephHackettoftheFDA.Joe'scontributionservesasa testimonytohisaccomplishmentsinthisfield,andhisinsightwillbemissed intheyearstocome.
Contents:
Toxicogenomics and Classical Toxicology: How to Improve Prediction and Mechanistic Understanding of Human Toxicity
Donna L. Mendrick Use of Traditional Endpoints and Gene Dysregulation to Understand Mechanisms of Toxicity: Toxicogenomics in Mechanistic Toxicology
Wayne R. Buck, Jeffrey F. Waring, Eric A. Blomme. Quality Control of Microarray Assays for Toxicogenomic and In Vitro Diagnostic Applications
Karol L. Thompson and Joseph Hackett Role of Statistics in Toxicogenomics
Michael Elashoff Predictive Toxicogenomics in Preclinical Discovery
Scott A. Barros and Rory B. Martin In Vivo Predictive Toxicogenomics
Mark W Porter Bioinformatics: Databasing and Gene Annotation
Lyle D. Burgoon and Timothy R. Zacharewski Microarray Probe Mapping and Annotation in Cross-Species Comparative Toxicogenomics
John N Calley, William B Mattes, and Timothy Ryan Toxicogenomics in Biomarker Discovery
Marc F. DeCristofaro and Kellye K. Daniels From Pharmacogenomics to Translational Biomarkers
Donna L. Mendrick Public Consortium Efforts in Toxicogenomics
William B. Mattes Applications of Toxicogenomics to Nonclinical Drug Development - Regulatory Science Considerations
Frank D. Sistare and Joseph J. DeGeorge
PRODUCT DETAILS
Publisher: Springer (Humana Press Inc.)
Publication date: November, 2010
Pages: 290
Weight: 513g
Availability: Available
Subcategories: Genetics, Pharmacology
Publisher recommends
From the same series
